Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E DeJesus

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Experimental Hematology|November 20, 2010
Transient neutropenia after granulocyte-colony stimulating factor administration is associated with neutrophil accumulation in pulmonary vasculatureCatherine E DeJesus, Jackson Egen, Mark Metzger, et al.
Plos One|November 6, 2018
Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosisPaulina J Villanueva, Alberto Martinez, Sarah T Baca, et al.
Oncogene|December 22, 1999
Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytesM Nesbit, H K Nesbit, J Bennett, et al.
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Cell Biology and Toxicology|March 3, 2019
A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulationDenisse A Gutierrez, Rebecca E DeJesus, Lisett Contreras, et al.
Human Gene Therapy|July 1, 1994
Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteinsL S Laube, M Burrascano, C E Dejesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2013
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimenR Campo, E DeJesus, U F Bredeek, et al.
Neoplasia (New York, N.Y.)|November 28, 2016
Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61Makoto Sano, David R Driscoll, Wilfredo E DeJesus-Monge, et al.
HIV Medicine|August 9, 2011
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patientsS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
HIV Medicine|August 14, 2018
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trialsD Hagins, C Orkin, E S Daar, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Experimental Hematology|November 20, 2010
Transient neutropenia after granulocyte-colony stimulating factor administration is associated with neutrophil accumulation in pulmonary vasculatureCatherine E DeJesus, Jackson Egen, Mark Metzger, et al.
Plos One|November 6, 2018
Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosisPaulina J Villanueva, Alberto Martinez, Sarah T Baca, et al.
Oncogene|December 22, 1999
Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytesM Nesbit, H K Nesbit, J Bennett, et al.
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Cell Biology and Toxicology|March 3, 2019
A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulationDenisse A Gutierrez, Rebecca E DeJesus, Lisett Contreras, et al.
Human Gene Therapy|July 1, 1994
Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteinsL S Laube, M Burrascano, C E Dejesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2013
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimenR Campo, E DeJesus, U F Bredeek, et al.
Neoplasia (New York, N.Y.)|November 28, 2016
Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61Makoto Sano, David R Driscoll, Wilfredo E DeJesus-Monge, et al.
HIV Medicine|August 9, 2011
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patientsS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
HIV Medicine|August 14, 2018
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trialsD Hagins, C Orkin, E S Daar, et al.
Pageof 3